Roche Plans Investment for its Basel Site
Roche reports that it will invest CHF 120 million ($134 million) to build new facilities at its headquarters in Basel, Switzerland, as well as to make upgrades to existing production operations at Basel. The company plans to build a new facility for small-molecule drugs, which it expects to have operational by the third quarter of 2016. In addition, it will invest another CHF 35 million ($39 million) to expand and upgrade an existing facility to make investigational drugs, as well as some products that are already approved.The facility is scheduled to be completed in June 2015.
The investment is in addition to the multiyear, CHF 800-million ($897 million) investment that the company announced in October 2013 to increase production capabilities for its biologic medicines at its sites in Penzberg, Germany, Basel, as well as Vacaville and Oceanside, California. That investment involves CHF 260 million ($291 million) for increasing biologics manufacturing capacity at its sites in Vacaville and Oceanside, CHF 350 million ($392 million) to increase manufacturing capacity and for equipment refurbishment at its site in in Penzberg, and CHF 190 million ($232 million) for construction of an antibody-drug conjugate production facility in Basel.
Source: Roche